Wall Street is paying attention to FBR’s George Zavoico’s surge in enthusiasm on Novavax’s prospects.
Mizuho’s Irina Rivkind Koffler is leaving the sidelines on Teba and boosting her price target, now angling for 19% upside.
Canaccord’s Mark Massaro is impressed that even after recent HTGM share volatility, the healthcare player still delivered an impressive robust fourth quarter turnout for 2017.
J.P. Morgan’s Doug Anmuth believes more advertisers are “re-engaging” with Twitter’s platform and sees exciting revenue gains coming next year.
MKM’s Ruben Roy now sees 27% upside potential for Micron shares ahead of its FQ1 results, believing memory trends are looking mostly positive.
H.C. Wainwright’s Ed Arce believes the market’s reaction is not on point, instead opting to recognize GALT’s NASH cirrhosis Phase 2b study as a “landmark,” clinically meaningful win.
Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.